Page 38 - 《中国药房》2021年3期
P. 38

Novel insights into the dynamics behavior of glucagon-  [13]  GAO L,LI SL,LI YK. Liraglutide promotes the osteoge-
             like peptide-1 receptor with its small molecule agonists[J].  nic differentiation in MC3T3-E1 cells via regulating the
             J Biomol Struct Dyn,2019,37(15):3976-3986.          expression of Smad2/3 through PI3K/Akt and Wnt/beta-
        [ 2 ]  WANG Z,WANG X,ZHANG L,et al. GLP-1 inhibits       catenin pathways[J]. DNA Cell Biol,2018,37(12):1031-
             PKC-β2 phosphorylation to improve the osteogenic diffe-  1043.
             rentiation potential of hPDLSCs in the AGE microenviron-  [14]  NISSEN A,MARSTRAND S,SKOV-JEPPESEN K,et al.
             ment[J]. J Diabetes Complications,2020. DOI:10.1016/J.  A pilot study showing acute inhibitory effect of GLP-1 on
             JDIACOMP.2019.107495.                               the bone resorption marker CTX in humans[J]. JBMR
        [ 3 ]  JACOME-GALARZA CE,PERCIN GI,MULLER JT,            Plus,2019. DOI:10.1002/JBM4.10209.
             et al. Developmental origin,functional maintenance and  [15]  YOUSEFZADEH N,KASHFI K,JEDDI S,et al. Ovariec-
             genetic rescue of osteoclasts[J]. Nature,2019,568(7753):  tomized rat model of osteoporosis:a practical guide[J].
             541-545.                                            EXCLI J,2020. DOI:10.17179/EXCLI2019-1990.
        [ 4 ]  PARIZAD N,BAGHI V,KARIMI EB,et al. The preva-  [16]  SANGHANI-KERAI A,MCCREARY D,LANCASHIRE
             lence of osteoporosis among Iranian postmenopausal  H,et al. Stem cell interventions for bone healing:fractures
             women with type 2 diabetes:a systematic review and me-  and osteoporosis[J]. Curr Stem Cell Res Ther,2018,13
             ta-analysis[J]. Diabetes Metab Syndr,2019,13(4):2607-  (5):369-377.
             2612.                                          [17]  SZULC P. Biochemical bone turnover markers in hormo-
        [ 5 ]  KNUDSEN LB,KIEL D,TENG M,et al. Small-molecule    nal disorders in adults:a narrative review[J]. J Endocrinol
             agonists for the glucagon-like peptide 1 receptor[J]. Proc  Invest,2020,43(10):1409-1427.
             Natl Acad Sci USA,2007,104(3):937-942.         [18]  DIEMAR SS,MOLLEHAVE LT,QUARDON N,et al. Ef-
        [ 6 ]  CHEONG YH,KIM MK,SON MH,et al. Two small mo-      fects of age and sex on osteocalcin and bone-specific alka-
             lecule agonists of glucagon-like peptide-1 receptor modu-  line phosphatase-reference intervals and confounders for
             late the receptor activation response differently[J]. Bio-  two bone formation markers[J]. Arch Osteoporos,2020.
             chem Biophys Res Commun,2012,417(1):558-563.        DOI:10.1007/S11657-020-00715-6.
        [ 7 ]  IRWIN N,FLATT PR,PATTERSON S ,et al. Insulin-re-  [19]  LEI T,LIANG Z,LI F,et al. Pulsed electromagnetic
             leasing and metabolic effects of small molecule GLP-1 re-  fields(PEMF)attenuate changes in vertebral bone mass,
             ceptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-bu-  architecture and strength in ovariectomized mice[J]. Bone,
             tylaminoquinoxaline[J]. Eur J Pharmacol,2010,628(1/2/  2018. DOI:10.1016/J.BONE.2017.12.008.
             3):268-273.                                    [20]  SCHIELLERUP SP,SKOV-JEPPESEN K,WINDELØV
        [ 8 ]  芦志伟,孙浩,李莹,等.长效GLP-1受体激动药索马鲁肽                      JA,et al. Gut hormones and their effect on bone metabo-
             治疗2型糖尿病疗效和安全性的系统评价[J].中国药房,                         lism. Potential drug therapies in future osteoporosis treat-
             2019,30(7):969-975.                                 ment[J]. Front Endocrinol(Lausanne),2019. DOI:10.
        [ 9 ]  李艳梅,唐祎偌,夏旋.索马鲁肽口服剂:开启GLP-1受体                      3389/FENDO.2019.00075.
             激动剂的新时代[J].药品评价,2019,16(24):1-3.               [21]  ZHANG Y,LIU MW,HE Y,et al. Protective effect of res-
        [10]  GRAAF CD,DONNELLY D,WOOTTEN D ,et al. Glu-         veratrol on estrogen deficiency-induced osteoporosis
             cagon-like peptide-1 and its class BG protein-coupled re-  though attenuating NADPH oxidase 4/nuclear factor kap-
             ceptors:a long march to therapeutic successes[J]. Pharma-  pa B pathway by increasing miR-92b-3p expression[J]. Int
             col Rev,2016,68(4):954-1013.                        J Immunopathol Pharmacol,2020. DOI:10.1177/205873-
        [11]  ZHOU C,ZHOU Y,WANG J,et al. Emergence of Chi-      8420941762.
             nese drug discovery research:impact of hit and lead identi-  [22]  WOOTTEN D,MILLER LJ. Structural basis for allosteric
             fication[J]. J Biomol Screen,2015,20(3):318-329.    modulation of class BG protein-coupled receptors[J]. An-
        [12]  ZHANG M,XIE Y,ZHOU Y,et al. Exendin-4 enhances     nu Rev Pharmacol Toxicol,2020. DOI:10.1146/AN-
             proliferation of senescent osteoblasts through activation of  NUREV-PHARMTOX-010919-023301.
             the IGF-1/IGF-1R signaling pathway[J]. Biochem Bio-          (收稿日期:2020-08-18  修回日期:2020-11-05)
             phys Res Commun,2019,516(1):300-306.                                                (编辑:唐晓莲)







        ·288 ·  China Pharmacy 2021 Vol. 32 No. 3                                    中国药房    2021年第32卷第3期
   33   34   35   36   37   38   39   40   41   42   43